Dexrazoxane for anthracycline extravasation and GM-CSF for skin ulceration and wound healing

Lancet Oncology

Volumn 5, Issue 5, 2004, Pages 320-321

  El Saghir, Nagi ^a   Otrock, Zaher ^a   Mufarrij, Afif ^a   Abou Mourad, Yasser ^a   Salem, Ziad ^a   Shamseddine, Ali ^a   Abbas, Jaber ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYCLOPHOSPHAMIDE; DIMETHYL SULFOXIDE; DOCETAXEL; DOXORUBICIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RAZOXANE;

ADULT; ARTICLE; BREAST CANCER; CASE REPORT; DOSE RESPONSE; DRUG EXTRAVASATION; DRUG INDICATION; DRUG RESEARCH; FASCIOCUTANEOUS FLAP; FEMALE; GRANULATION TISSUE; HISTOPATHOLOGY; HUMAN; LEUKOPENIA; LIVER TOXICITY; PRIORITY JOURNAL; SKIN GRAFT; SKIN ULCER; SYSTEMIC DISEASE; THROMBOCYTOPENIA; TISSUE NECROSIS; TREATMENT OUTCOME; WOUND HEALING;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHELATING AGENTS; CLINICAL TRIALS, PHASE III; COMBINED MODALITY THERAPY; DOXORUBICIN; EXTRAVASATION OF DIAGNOSTIC AND THERAPEUTIC MATERIALS; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRALESIONAL; RANDOMIZED CONTROLLED TRIALS; RAZOXANE; SKIN ULCER; THORAX; WOUND HEALING;

EID: 2142658874     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(04)01470-6     Document Type: Article

References (12)

1. El Saghir NS Bizri AR Shabb NS et al. Pressure-ulcer accelerated healing with local injections of granulocyte-macrophage colony-stimulating factor J Infect 35 1997 179-182
2. Shamseddine AI Khalil AM Kibbi AG et al. Granulocyte-macrophage colony- stimulating factor for treatment of chemotherapy extravasation Eur J Gynaecol Oncol 19 1998 479-481
3. Rudolph R Larson DL. Etiology and treatment of chemotherapeutic-agent extravasation injuries: a review J Clin Oncol 5 1987 1116-1126
4. Blum RH. Clinical status and optimal use of the cardioprotectant, dexrazoxane Oncology (Huntingt) 11 1997 1669-1678
5. Langer SW Sehested M Jensen PB et al. Dexrazoxane in anthracycline extravasation J Clin Oncol 18 2000 3064
6. Jensen JN Lock-Andersen J Langer SW Mejer J. Dexrazoxane: a promising antidote in the treatment of accidental extravasation of anthracyclines Scand J Plast Reconstr Surg Hand Surg 37 2003 174-175
7. Bos AM van der Graaf WT Willemse PH. A new conservative approach to extravasation of anthracyclines with dimethylsulfoxide and dexrazoxane Acta Oncol 40 2001 541-542
8. Schroeder PE Davidson JN Hasinoff BB. Dihydroorotase catalyzes the ring opening of the hydrolysis intermediates of the cardioprotective drug dexrazoxane (ICRF-187) Drug Met Disp 30 2002 1431-1435
9. Ozer H Armitage JO Bennett CL et al. Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel J Clin Oncol 18 2000 3558-3585
10. Arnaout MA Wang FA Clark SC Sieff CS. Human recombinant granulocyte-macrophage colony-stimulating factor increases cell-to-cell adhesion and surface expression of adhesion-promoting surface glycoproteins on mature granulocytes J Clin Invest 78 1986 597-601
11. Montagnani S Postiglione L Giordano-Lanza G et al. Granulocyte- macrophage colony-stimulating factor (GM-CSF) biological actions on human dermal fibroblasts Eur J Histochem 45 2001 219-228
12. Marques da Costa R Jesus FM Aniceto C Mendes M. Double-blind randomized placebo-controlled trial of the use of granulocyte-macrophage colony-stimulating factor in chronic leg ulcers Am J Surg 173 1997 165-168